产品
编 号：F420789
分子式：C28H44N4O8
分子量：564.67
分子式：C28H44N4O8
分子量：564.67
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 666843-10-3
产品详情
生物活性：
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation.
体内研究：
Mizagliflozin (DSP-3235 free base) (3-30 mg/kg；口服) 具有通便作用。 Mizagliflozin 静脉给药 (0.3 mg/kg) 与口服给药 (3 mg/kg) 相比半衰期下降，分别为 0.23 和 1.14 小时。Animal Model:Male Wistar rats (rat model of low-fiber-diet-induced constipation)
Dosage:3, 10, 30 mg/kg
Administration:Oral
Result:Increased fecal wet weight in a rat model of low-fiber-diet-induced constipation.
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation.
体内研究：
Mizagliflozin (DSP-3235 free base) (3-30 mg/kg；口服) 具有通便作用。 Mizagliflozin 静脉给药 (0.3 mg/kg) 与口服给药 (3 mg/kg) 相比半衰期下降，分别为 0.23 和 1.14 小时。Animal Model:Male Wistar rats (rat model of low-fiber-diet-induced constipation)
Dosage:3, 10, 30 mg/kg
Administration:Oral
Result:Increased fecal wet weight in a rat model of low-fiber-diet-induced constipation.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备